Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
Neuropace的股票在公司报告了好于预期的第三季度财务结果并提高了2024财年的销售指引后上涨。富国银行对该股票维持超配评级。
Neuropace Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Sales Guidance. Wells Fargo Maintained an Overweight Rating on the Stock.
Neuropace的股票在公司发布超出预期的第三季度财务结果并上调2024财年销售指引后交易上涨。富国银行对该股票维持超配评级。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间